FULLY HUMANIZED MONOCLONAL NEUTRALIZING ANTIBODIES FOR TETANUS TOXIDANT AND ITS USE
Patent Information
- Application Number
- DE602018091990
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-05-04
- Filing Date
- 2018-12-28
- Publication Date
- 2026-06-24
- Estimated Expiration
- 2038-12-28
AI Technical Summary
Current tetanus toxin treatments, such as human tetanus immunoglobin (HTIG) and tetanus antitoxin from horse serum, face challenges including adverse reactions, scarce human blood sources, high costs, and risks of virus contamination, while existing monoclonal antibodies do not provide sufficient protection against tetanus toxin.
Development of fully native human neutralizing monoclonal antibodies with high affinity and specificity, encoded by specific sequences, for tetanus toxin, which can be produced in large quantities without immunogenicity or exogenous virus contamination, and used for diagnosis, prevention, and therapy.
The antibodies offer high efficacy in neutralizing tetanus toxin, are safe, and can be widely used, providing effective prevention and treatment with reduced risks of allergic reactions and contamination.